Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Leukemias - Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis Poster II

Sunday, December 7, 2008: 6:00 PM-8:00 PM
Hall A (Moscone Center)
The CD34+CD38LowCD19+ Candidate Leukemic Stem Cell Phenotype Revisited: Useful for Flow MRD Monitoring?

Kerrie Wilson, BSc, (Hons)1*, Marian Case, MSc1*, Lynne Minto1*, Simon Bailey, MD, PhD, FRCPCH2*, Josef Vormoor, MD, FRCPCH1 and Julie Irving, PhD1

1Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
2Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, United Kingdom

Suppressed CEBPA Function Is Associated with Favorable Prognosis in Normal Karyotype AML Patients

Jose Fos1*, Nicola Bonadies1*, Thomas Pabst2 and Beatrice U Mueller1*

1Department for Internal Medicine and Clinical Research, University Hospital Berne, Berne, Switzerland
2Institute of Medical Oncology, Berne, Switzerland

The Genotype Consisting of Complex Karyotype and TP53 Gene Mutation Is Specific to Acute Myeloid Leukemia with Multilineage Dysplasia

Yuichi Ishikawa, M.D.1*, Hitoshi Kiyoi, M.D.Ph.D2, Akane Tsujimura, MD1*, Yasushi Miyazaki, M.D.Ph.D3, Masao Tomonaga, M.D.Ph.D3, Kazutaka Kuriyama, M.D.Ph.D4*, Shuichi Miyawaki, M.D.Ph.D5 and Tomoki Naoe, M.D.Ph.D1

1Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
2Department of Infectious Disease, Nagoya University School of Medicine, Nagoya, Japan
3Hematology and Molecular Medicine, Nagasaki University School of Medicine, Nagasaki, Japan
4Hematoimmunology, University of Ryukyus, Uehara, Japan
5Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan

Overexpression of HIF1 Alpha Predicts Worse Overall and Event-Free Survival in Patients with  Philadelphia Chromosome-Negative Precursor B-Lymphoblastic Leukemia

S. Konoplev1, S.M. Kornblau1*, E. Schlette1*, H Lu1*, D. A Thomas1*, N Zhang1*, Y.H. Qiu1*, K Coombes1*, S. Neeley1*, Hagop M Kantarjian2*, L.J. Medeiros1*, M. Andreeff1* and M. Konopleva1

1The University of Texas M.D. Anderson Cancer Center, Houston, TX
2M.D. Anderson Cancer Center, Houston, TX

Deficient Apoptosis Signaling in Primary Pediatric BCP-ALL Xenograft Cells Determines the Kinetic of Engraftment in Vivo in a NOD/SCID Model and Patient Outcome

Manon Queudeville, MD*, Sarah M. Eckhoff, MD*, Karsten Stahnke, MD*, Klaus-Michael Debatin, MD and Lueder H. Meyer, MD*

Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany

Reverse Phase Protein Assay (RPPA) Defines Specific Patterns in Childhood Acute Lymphoblastic Leukemia (ALL)

Manuela Tumino, M.D.1*, Benedetta Accordi, Ph.D.2*, Manuela Sciro, B.D.2*, Marco Giordan, Statistician2*, Geertruy te Kronnie, Ph.D.2*, Giuseppe Basso, M.D., Ph.D., Full, Professor2* and Luca Lo Nigro, M.D., Ph.D.3

1Center of Pediatric Hematology Oncology, University of Catania, Catania, Italy
2Department of Pediatrics, University of Padova, Padova, Italy
3Center of Pediatric Hematology Oncology, Azienda Policlinico - University of Catania, Catania, Italy

Single-Cell Phospho-Profiling in Pediatric Acute Lymphoblastic Leukemia (ALL) Reveals Constitutive and Cytokine Induced Specific Signatures Involving Stat5

Manon Queudeville, MD*, Hannah Kunze*, Sarah M. Eckhoff, MD*, Klaus-Michael Debatin, MD and Lueder H. Meyer, MD*

Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany

Prognosis of ProB ALL in Children

Ondrej Hrusak1, Ester Mejstrikova, MD1*, Katerina Zdrahalova2*, Karolina Kramarzova1*, Martin Kovac1*, Jan Trka, MD, PhD1 and Jan Stary, MD, PhD2*

1Pediatric Hematology and Oncology, 2nd Medical School, Charles University Prague, CLIP - Childhood Leukemia Investigation Prague, Prague, Czech Republic
2Pediatric Hematology and Oncology, 2nd Medical School, Charles University Prague, Prague, Czech Republic

A New Subtype of Excellent Prognosis Identified by GEP in Childhood BCP-ALL Patients

Elena Vendramini1*, Marco Giordan, PhD1*, Silvia Bresolin1*, Luca Trentin1*, Andrea Zangrando, PhD1*, Giulia Fabbri1*, Geertruy Kronnie, PhD1 and Giuseppe Basso, MD2*

1Pediatrics, University of Padova, Padova, Italy
2Dept. Pediatrics, University of Padova, Padova, Italy

Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1

Sabine Kayser1*, Richard F. Schlenk1*, Frank Breitenbücher2*, Martina Porebski3*, Kerstin Wittke1*, Juan Du3*, Silja Groner1*, Daniela Spaeth1*, Jürgen Krauter4*, Arnold Ganser4, Hartmut Döhner1*, Thomas Fischer5* and Konstanze Döhner1*

1Internal Medicine III, University of Ulm, Ulm, Germany
2University of Essen, Essen, Germany
3University of Ulm, Ulm, Germany
4Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
5Department of Hematology/Oncology, University of Magdeburg, Magdeburg, Germany

Molecular Response to Treatment Predicts Outcome in Isolated, but Not in Combined Bone Marrow Relapses of Childhood Acute Lymphoblastic Leukaemia: Interim Results of Trial ALL-REZ BFM 2002Clinically Relevant Abstract

Cornelia Eckert, PhD*, Arend Stackelberg, MD*, Nikola Hagedorn*, Andrea Barth*, Karl Seeger, MD, PhD* and Guenter Henze, Prof., MD*

Department of Pediatric Oncology/Hematology, Charité - Medical University, Berlin, Germany

Wilms Tumor 1 Gene Mutations in Adult Acute T-Lymphoblastic Leukemia

Sandra Heesch, MS1*, Nicola Goekbuget, MD2, Jutta Ortiz Tanchez1*, Cornelia Schlee, MS1*, Stefan Schwartz, Dr.3*, Thomas Burmeister, MD1*, Dieter Hoelzer, MD, PhD4, Eckhard Thiel, MD, PhD3, Wolf K Hofmann, MD1* and Claudia D Baldus, MD1*

1Hematology, Oncology, Charite, Campus Benjamin Franklin, Berlin, Germany
2Medical Department II, J.W.Goethe University, Frankfurt, Germany
3Medizinische Klinik III (Haematologie, Onkologie und Transfusionsmedizin), Charite Campus Benjamin Franklin (Charite Centrum 14), Berlin, Germany
4J.W. Goethe University Hospital, Frankfurt/M, Germany

The Role of Activation-Induced C-Type Lectin (AICL) in NK Cell Reactivity against Acute Leukemia

Tina Baessler1*, Sabrina Kuttfruff2*, Matthias Krusch1*, Lothar Kanz1, Alexander Steinle2* and Helmut R Salih1

1Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany
2Immunology, Eberhard Karls University, Tuebingen, Germany

The Detection of Multilineage Dysplasia (MLD) Has No Influence on Prognosis in NPM1 Mutated Acute Myeloid Leukemia (AML) with Normal Karyotype

Ulrike Bacher, MD1*, Susanne Schnittger, PhD2, Wolfgang Kern, MD2, Tamara Weiss2*, Claudia Haferlach, MD2, Brunangelo Falini, MD3* and Torsten Haferlach, MD2

1Department of Stem Cell Transplantation, University Cancer Center Hamburg (UCCH), Hamburg, Germany
2MLL Munich Leukemia Laboratory GmbH, Munich, Germany
3Hematology and Clinical Immunology, University of Perugia, Perugia, Italy

Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis

Jeffrey W Tyner, PhD1*, Heidi Erickson2*, Stephen Oh, MD, PhD3, Jason R. Gotlib4*, Michael W.N. Deininger, MD1, Brian J. Druker1 and Marc Loriaux, MD, PhD1*

1Oregon Health & Science University Cancer Institute, Portland, OR
2Oregon Health & Science University, Portland, OR
3Division of Oncology, Stanford University, Palo Alto, CA
4Stanford Cancer Center, Stanford Univ., Stanford, CA

Absolute Lymphocyte Count at 1st Remission Is Prognostic Factor for Disease Free and Overall Survival for Acute Myeloid Leukemia Under 60: Analysis of AML1 GOELAMS Trial

Bruno Lioure, MD1*, Christian Recher, M.D;, Ph.D2*, Patrice Chevallier, MD3*, Arnaud Pigneux, MD, PhD4*, Francis Witz5*, Norbert Vey, MD6, Nathalie Fegueux, MD7*, Claude-Eric Bulabois8*, Sylvie Daliphard9*, Fabrice Larosa10*, Martine Escoffre-Barbe, MD11*, Eric Jourdan, MD, PhD12*, Olivier Tournilhac, MD, PhD13*, Martine Delain, MD14*, Denis Caillot15*, Mario Ojeda, MD16*, Edouard Randriamalala, MD17*, Roselyne Delepine18*, Francois Dreyfus19* and Norbert Ifrah, MD20

1Département d'Hématologie et d'Oncologie, CHU Hautepierre, Strasbourg, France
2Service d'Hematologie, CHU Toulouse, Toulouse, France
3Hematology, CHU Hotel-Dieu, Nantes, France
4CHU Bordeaux, Bordeaux, France
5Hématologie - Médecine interne, Hôpitaux de Brabois, Nancy, France
6Dept. of Hematology, Institut Paoli Clamettes, Marseille, France
7Service Oncologie et Hématologie, Hôpital Lapeyronie, Montpellier, France
8Hematology department, CHU Grenoble, Grenoble, France
9Laboratoire d'Hematologie, CHU Reims, Reims, France
10Hematology, INSERM UMR645 - CHU Jean Minjoz, Besancon
11Hematologie, CHU Rennes, Rennes, France
12Médecine B – Unité Onco-Hématologie, Hôpital Caremeau, Nimes, France
13Hematology, CHU Clermont Ferrand, Clermont Ferrand, France
14Service d'Hématologie et Thérapie Cellulaire, CHU de Tours, Tours, France
15IFM, CHU Bocage, Dijon, France
16Hematologie, CH Mulhouse, Mulhouse, France
17Hematologie, CHU Poitiers, Poitiers, France
18Hematologie, CHU Tours, Tours, France
19Hematologie, CHU Cochin, Paris, France
20Service des Maladies du Sang, CHU d'Angers, Angers, France

SNP Array-Based Analysis of Chromosome 17 Reveals Biallelic TP53 Mutations Due to Uniparental Disomy 17p in Advanced MDS and AML with Cooperating Deletions of Chromosomes 5 and 7

Monika Jasek1*, Lukasz P. Gondek1*, Nelli Bejanyan1*, Ramon V. Tiu1, Jungwon Huh1*, Karl S. Theil2, Christine O' Keefe1*, Michael A. McDevitt3 and Jaroslaw P. Maciejewski1

1Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
2Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH
3Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

Prognostic Value of Molecular Markers for Guiding Post-Remission Therapy in Patients with De Novo Acute Myeloid Leukemia (AML) and Intermediate-Risk Cytogenetics

Marta Pratcorona1*, Mireia Camós2*, Montserrat Torrebadell2*, Maria Rozman2*, Ana Carrió2*, Dolors Costa2*, Alexandra Valera2*, Elias Campo2*, Emili Montserrat1 and Jordi Esteve1

1Institute of Hematology and Oncology, Department of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
2Hematopathology Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain

Deletion 5q in AML: A Clinicopathological Description of 79 Cases from a Single Institution

Rafael Santana-Davila, MD1, Shernan G. Holtan, MD1, Rhett Ketterling, MD2*, Ryan A Knudson2*, David P. Steensma, MD, FACP1, Dong Chen, MD, PhD3, James Hoyer, MD4, Curtis A Hanson, MD5* and Ayalew Tefferi, MD6

1Division of Hematology, Mayo Clinic, Rochester, MN
2Laboratory Med. & Pathology, Mayo Clinic, Rochester, MN
3Division of Hematopathology, Mayo Clinic, Rochester, MN
4Mayo Clinic, Rochester, MN
5Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN
6Medicine, Division of Hematology, Mayo Clinic Graduate School of Medicine, Rochester, MN

Zidovudine Blocks NF-κB activity in Vivo in Adult T-Cell Leukemia

Juan Carlos Ramos, MD1, Luis M. Diaz2*, Michele Manrique2*, Rosangela Lima3*, Ngoc L Toomey2*, Tianli Xia2*, Lisa Cabral2*, Toumy Guettouche2*, Carlos Brites3* and William J. Harrington, MD2*

1Medicine, Division of Hematology/Oncology, University of Miami, Miami, FL
2Sylvester Cancer Center, Division of Hematology & Oncology, Miami, FL
3Federal University of Bahia, Salvador, Brazil

Mathematical Modeling of Molecular Relapse Kinetics in NPM1c+, PML-Rara+, RUNX1-RUN1T1+, and CBFB-MYH11+ Acute Myeloid Leukemias

Hans Beier Ommen1*, Susanne Schnittger2, Jelena V Jovanovic3*, Ingrid Beier Ommen1*, Henrik Hasle4, Mette Oestergaard1*, David Grimwade3 and Peter Hokland1

1Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
2MLL Munich Leukemia Laboratory GmbH, Munich, Germany
3Department of Medical and Molecular Genetics, King's College London School of Medicine, London, United Kingdom
4Department of Pediatrics, Aarhus University Hospital, Skejby, Aarhus, Denmark

Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cytoreduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL)

Peter Rhein1*, Richard Ratei, MD1*, Rita Mitlohner1*, Giuseppe Basso, MD2*, Giuseppe Gaipa, MD3*, Michael N Dworzak, MD, PhD4*, Martin Stanulla, MD5*, Martin Schrappe, MD5, Wolf-Dieter Ludwig, MD1 and Leonid Karawajew, PhD1*

1Dept. of Hematology, Oncology, and Tumor Immunology, Robert-Rossle-Clinic at the HELIOS Klinikum Berlin-Buch, Charité, Berlin, Germany
2Dept. of Pediatrics, University of Padova, Padova, Italy
3M.Tettamanti Research Center, Pediatric Clinic University of Milan Bicocca, Monza, Italy
4Children's Cancer Research Institute and St. Anna Children's Hospital, Vienna, Austria
5Dept. of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

About 17% of AML with NPM1 mutations Show a Specific Pattern of Chromosome Aberrations but These Cases Do Not Differ Prognostically from AML with NPM1 Mutations Carrying a Normal Karyotype

Claudia Haferlach, MD1, Susanne Schnittger, PhD1, Tamara Weiss1*, Wolfgang Kern, MD1, Brunangelo Falini, MD2* and Torsten Haferlach, MD1

1MLL Munich Leukemia Laboratory GmbH, Munich, Germany
2Hematology and Clinical Immunology, University of Perugia, Perugia, Italy

Overexpression of the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated with a High Incidence of Relapses in Childhood Acute Myeloid Leukemia Treated with G‑CSF

Stephanie Ehlers, MD1*, Christin Herbst1*, Martin Zimmermann, PhD2*, Nicole Scharn1*, Manuela Germeshausen, PhD3, Claudia Langebrake, PhD4*, Thomas Lehrnbecher, MD5*, Jochen Harbott, PhD6, Jan Stary, MD, PhD7*, Michael Dworzak, MD8*, Ursula Creutzig, MD9 and Dirk Reinhardt, MD, PhD10

1Department of Pediatric Hematology and Oncology, Medical School Hannover, 30625 Hannover, Germany
2Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany
3Ped. Hem. Onc., Medical School Hannover, Hannover, Germany
4Department of Pediatric Hematology and Oncology, University Hamburg, Hamburg, Germany
5Pediatric Hematology and Oncology, University of Frankfurt, Frankfurt, Germany
6Department of Paediatric Haematology/Oncology, Oncogenetic Laboratory, Justus-Liebig-Universität Giessen, Giessen, Germany
7Dept of Pediatric Hematology and Oncology, 2nd Medical School, Charles University, University Hospital Motol, Prague, Czech Republic
8St Anna Kinderspital and Childrens Cancer Research Institute, Vienna, Austria
9Universitats-Kindeklinik, Munster, Germany
10Paediatric Haematology/Oncology, Hannover Medical School, Hannover, Germany

MRD Monitoring Reveals a Specific Biology of BCR/ABL-Positive ALL

Marketa Zaliova1*, Leona Reznickova1*, Eva Fronkova1*, Katerina Krejcikova1*, Katerina Muzikova1*, Claus Meyer2*, Rolf Marschalek2*, Jan Stary1*, Jan Trka1 and Jan Zuna1

1Pediatric Hematology and Oncology, 2nd Medical School, Charles University Prague, CLIP - Childhood Leukemia Investigation Prague, Prague, Czech Republic
2Institute of Pharmaceutical Biology, ZAFES, Diagnostic Center of Acute Leukemia, Goethe-University of Frankfurt, Biocenter, Frankfurt/Main, Germany

Multiplex Quantum Dot ISH Measurement of Gene Expression in Tissue Microarrays Identifies HOXA9 and DNMT3A as Markers of Poor Response to Chemotherapy in Patients with Acute Myeloid Leukaemia

Eleni Tholouli, MD, MRCP, MRCPath1*, Sara A MacDermott2*, Judith A Hoyland, PhD3*, Caroline Glennie2*, Ric Swindell4*, John Liu-Yin, FRCP, FRCPath5 and Richard J Byers, PhD, MRCPath2*

1Haematology, Manchester Royal Infirmary, Manchester, United Kingdom
2Histopathology, Manchester Royal Infirmary, Manchester, United Kingdom
3Department of Regenerative Medicine, Manchester University, Manchester, United Kingdom
4Statistics, Christie Hospital, Manchester, United Kingdom
5Clinical Haematology, Manchester Royal Infirmary, Manchester, United Kingdom

Age-Dependent Frequencies of NPM-1/FLT3-ITD Mutations in Patients with Normal Karyotype AML

Friederike Schneider1*, Eva Hoster1*, Michael Unterhalt1*, Stephanie Schneider1*, Annika Dufour1*, Tobias Benthaus1*, Gudrun Mellert1*, Evelyn Zellmeier1*, Stefan K. Bohlander1*, Michaela Feuring-Buske1*, Christian Buske1, Jan Braess1*, Achim Heinecke2*, Maria C. Sauerland2*, Wolfgang E. Berdel3, Thomas Buechner3*, Wolfgang Hiddemann1 and Karsten Spiekermann1*

1Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Munich, Campus Grosshadern, Munich, Germany
2Dept. of Medical Informatics and Biomathematics, University of Muenster, Muenster, Germany
3Department of Medicine, Hematology and Oncology, University of Muenster, Muenster, Germany

Risk of Leukemia in Genetic Subgroups of Congenital Neutropenia (CN): Comparison of Patients with Mutations in  HAX1 or ELA2

Cornelia Zeidler, MD1*, Jean Donadieu, MD2*, Gusal Pracht1*, Blandine Beaupain2*, Ludwig Hoy, PhD3*, Martin Zimmermann, PhD4*, Christine Bellanne-Chantelot5*, Christoph Klein6, Manuela Germeshausen7* and Karl Welte1*

1Pediatric Hematology / Oncology, SCNER, Medical School Hannover, Hannover, Germany
2Service d'Hémato-Oncologie Pédiatrique, Hopital Trousseau, French Neutropenia Registry, Paris, France
3SCNER
4Pediatric Hematology/Oncology, SCNER, Medical School Hannover, Hannover, Germany
5Department of Genetics, AP-HP Pitié-Salpétriére, Paris, France
6Department of Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany
7Paed. Hematology/Oncology, SCNER, Hannover, Germany

Flow Cytometric Detection of BCR-ABL Fusion Proteins in Leukemia Patients Via An Immunobead Assay

Floor Weerkamp1*, E. Dekking2*, Vincent H.J. Van der Velden1*, Sebastian Böttcher3*, Nancy Boeckx4*, Elisabeth R. Van Wering5*, Juan Flores Montero6*, Paulo Lucio7*, Lukasz Sedek8*, Tomas Kalina9*, Elizabeth Macintyre10*, Frank J.T. Staal1* and Jacques JM van Dongen, Ph.D11

1Immunology, Erasmus MC, Rotterdam, Netherlands
2Immunology, Dynomics B.V. / Erasmus MC, Rotterdam, Netherlands
3Second Department of Medicine, University of Schleswig-Holstein, Kiel, Germany
4Laboratory Medicine, Hematology, University Hospitals Leuven, Leuven, Belgium
5Dutch Childhood Oncology Group, Netherlands
6Laboratorio de Hematologica, University of Salamanca, Salamanca, Spain
7Laboratorio de hemato-oncologia, Institute of Molecular Medicine, Lisbon, Portugal
8Pediatric Hematology and Oncology, Medical University of Silesia, Zabrze, Poland
9Dept. of Paediatric Haematology/Oncology, Charles University, Prague, Czech Republic
10Laboratoire d'Hematologie, Hôpital Necker, Paris, France
11Department of Immunology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

Minimal Residual Disease Monitoring in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with Arsenic Trioxide

Ezhilarasi Chendamarai, MSc*, Poonkuzhali Balasubramanian, PhD*, Kavitha Lakshmi, MSc*, Auro Viswabandya, MD*, Biju George, MD*, Alok Srivastava, MD*, Mammen Chandy, MD* and Vikram Mathews, MD

Haematology, Christian Medical College, Vellore, India

Clinical and Biological Characterization of Adult Patients with Acute Myeloid Leukemia Bearing T(7;11)(p15;p15)—Analysis of 536 Patients

Wen-Chien Chou1, Chien-Yuan Chen2*, Hsin-An Hou2*, Liang-In Lin3*, Jih-Luh Tang2*, Ming Yao2*, Woei Tsay2*, Bor-Shen Ko2*, Shan-Yi Huang2* and Hwei-Fang Tien2*

1Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan
2Dept. Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
3Graduate Institute of Medical Biotechnology, National Taiwan University Hospital, Taipei, Taiwan

Protein Expression in Acute Myelogenous Leukemia Stem Cells Compared to Bulk AML Cells Using Reverse Phase Proteins Arrays (RPPA)

Steven M. Kornblau, MD*, YiHua Qiu*, David Graber*, Wenjing Chen*, Jose Melendez*, Marina Konopleva, Stefan Faderl*, Michael Andreeff*, Gautam Borthakur*, Hui Yao* and Kevin R. Coombes*

M.D. Anderson Cancer Center, Houston, TX

High Leukemic Stem Cell Frequency in Remission Bone Marrow Predicts Poor Outcome in Acute Myeloid Leukemia

Monique Terwijn, MSc*, Angèle Kelder*, Arjo P Rutten*, Gert J Ossenkoppele, MD, PhD, Sonja Zweegman, MD, PhD and Gerrit Jan Schuurhuis, PhD*

Department of Hematology, VU University Medical Center, Amsterdam, Netherlands

Mutant Wilms’ Tumor 1 (WT1) mRNA with Premature Termination Codons Is Sensitive to Nonsense-Mediated RNA Decay in Acute Myeloid Leukemia (AML)

Saman Abbas*, Claudia Erpelinck*, Chantal Goudswaard*, B. Lowenberg, MD and Peter Valk, PhD

Hematology, Erasmus University Medical Center, Rotterdam, Netherlands

Selective Expression of the Immunoregulatory Lectin, Galectin-1, in Precursor B Cell Acute Lymphoblastic Leukemias (ALLs) with MLL Rearrangements

Przemyslaw Juszczynski, MD, PhD1, Scott J. Rodig, MD, PhD2*, Kunihiko Takeyama, MD, PhD1, Jing Ouyang, PhD1*, Jorg Faber, MD, PhD3, Scott Armstrong, MD, PhD3, Jeffery L. Kutok, MD, PhD2 and Margaret A. Shipp, MD1

1Dana-Farber Cancer Institute, Boston, MA
2Brigham & Women's Hospital, Boston, MA
3Children's Hospital, Boston, MA

Changes in Type I Mutations Between Initial and Relapse Samples of Pediatric AML Patients Occur Frequently and Are Associated with Time to Relapse

Costa Bachas, MSc1*, Gerrit J. Schuurhuis, PhD2, Lê D Huynh, BSc1*, Bianca F. Goemans, MD, PhD1, D. Reinhardt, MD, PhD3, Gertjan Kaspers, MD, PhD1 and Jacqueline Cloos, PhD1*

1Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, Netherlands
2Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
3BFM-G, Hannover, Germany

Improved Prognosis of Children and Adolescents with Acute Lymphoblastic Leukemia (ALL) and Very-High Minimal Residual Disease (MRD) and the End of Induction therapy (EOI)? Preliminary Results of the FRALLE 2000 ProtocolClinically Relevant Abstract

Jean-Michel Cayuela1*, Kheira Beldjord2*, Sylvie Fasola3*, Marie-Françoise Auclerc, MD4*, Benoît Brethon1*, Anne Auvrignon5*, Francoise Mechinaud6*, Virginie Gandemer, MD7*, Geneviève Margueritte8*, Pascale Blouin9*, Nathalie Grardel10*, Hélène Cavé11*, Elizabeth Macintyre12*, Leverger Leverger, MD, PhD3* and Andre Baruchel, MD13

1Hôpital St-Louis, Paris, France
2Hôpital Necker, Paris
3Pediatric Hematology Oncology, Hôpital Armand Trousseau, Paris, France
4Hopital Saint Louis, Paris, France
5Hopital Trousseau, Paris, France
6Hematology, CHU Hotel-Dieu, Nantes, France
7CHU, Rennes
8CHU Montpellier, Montpellier
9CHU, Tours
10CHRU, Lille
11Hôpital Robert Debré, Paris
12Laboratoire d'Hematologie, Hôpital Necker, Paris, France
13Dept. of Pediatric Hematology, Hopital Saint Louis, Paris, France

Prognostic Impact of Mutations in the Nucleophosmin (NPM1) and of the FMS-Related Tyrosine Kinase 3 (FLT3) Genes in Elderly Patients with Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy

Anne Etienne1*, Cecile Borel2*, Sarah Reutenauer2*, Sylviane Olschwang3*, Marie-Joelle Mozziconacci3*, Eric Delabesse4*, Cecile Demur4*, Thomas Prebet1*, Francoise Huguet2*, Aude Charbonnier1*, Christian Recher2* and Norbert Vey1

1Hematology, Institut Paoli-Calmettes, Marseille, France
2Service d'Hematologie, CHU Toulouse, Toulouse, France
3Biopathologie, Institut Paoli-Calmettes, Marseille, France
4Laboratoire d'Hématologie, CHU Toulouse, Toulouse, France

Discordance of MLL-Rearranged (MLL-R) Infant ALL in Monozygotic Twins with Spontaneous Clearance of Preleukemic Clone in Unaffected Twin

Meredith Chuk, MD1*, Emily McIntyre2*, Donald Small, MD, PhD2 and Patrick Brown, MD2

1Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
2Oncology and Pediatrics, Johns Hopkins University, Baltimore, MD

Correlation Between Cytogenetic Aberrations Detected by Conventional Chromosome Banding Analysis and Specific Immunophenotypes in Patients with B-Cell Lymphoproliferative Diseases

Wolfgang Kern, MD, Torsten Haferlach, MD, Susanne Schnittger and Claudia Haferlach, MD

MLL Munich Leukemia Laboratory GmbH, Munich, Germany

Direct Visualization of PR1/HLA-A2 on the Membrane of HLA-A2+CD13+CD33+ Myeloid Leukemia Blasts by a Novel Monoclonal Antibody

Anna Sergeeva1*, Sijie Lu1*, James N Wygant2*, Gheath Alatrash1*, Kathryn Quintanilla1* and Jeffrey J. Molldrem, MD1

1Stem Cell Transplantation and Cellular Therapy, M. D. Anderson Cancer Center, Houston, TX
2Immunology, M. D. Anderson Cancer Center, Houston, TX

Distinct Gene Expression Profiling in AML in Elderly Versus Younger Patients

Henk-Marijn de Jonge1*, Evelina S de Bont1*, Peter Valk2, Jan Jacob Schuringa3, Marcel P Kies3*, Carolien M. Woolthuis3*, Ruud Delwel2, Edo Vellenga3, B. Lowenberg2 and Geert A Huls3

1Pediatric Oncology/Hematology, University Medical Center Groningen, Groningen, Netherlands
2Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
3Department of Hematology, University Medical Center Groningen, Groningen, Netherlands

Prognosis of Patients with AML Carrying 11Q23/MLL Reciprocal Translocations : A Retrospective Study of 191 Cases from the French AML-Intergroup

Anne Banos1*, Antoine Jaquet2*, Anne Auvrignon3*, Nicole Dastugue4*, Christine Terré5*, Isabelle Luquet, MD, PhD6*, Sylvie Castaigne5*, Marina lafage Pochitaloff7*, Thierry Leblanc8*, Pierre Fenaux, MD, PhD9*, Francoise Huguet10*, Francis Witz11*, Didier Blaise12*, Josy M. Reiffers13*, Jean Luc Harousseau14*, Gerard Socie, MD15*, Bruno Lioure, MD16*, Christian Bastard17*, Herve Dombret, MD18 and Arnaud Pigneux, MD, PhD19*

1Service Hematologie, Centre Hospitalier De La Cote Basque, Bayonne, France
2Statistique, Faculte de bordeaux, Bordeaux, France
3Hopital Trousseau, Paris, France
4Laboratoire d'Hématologie, Hôpital Purpan, Toulouse, France
5Hôpital Mignot, Versailles, France
6Laboratoire central d'Hématologie, Hôpital Robert Debré, Reims, France
7Biopathologie, Institut Paoli-Calmettes, Marseille, France
8Pediatric Hematology, Hôpital Saint Louis, Paris, France, Paris, France
9Hôpital Avicenne/ Université Paris 13, Bobigny, France
10CHU de Toulouse, Toulouse, France
11Hématologie - Médecine interne, Hôpitaux de Brabois, Nancy, France
12Hematology, CHU de Marseille, Marseille, France
13CRLCC Institut Bergonié, Bordeaux,, France
14Service d'Hématologie, CHU Hotel Dieu, Nantes, France, NAntes, France
15Hopital Saint-Louis, Paris, France
16Oncology and Hematology, Hopital de Hautepierre, Strasbourg Cedex, France
17Hematology, INSERM U918, Centre Henri Becquerel, Rouen, France
18Hopital Saint Louis, Paris, France
19CHU Bordeaux, Bordeaux, France

Unlike Paediatric T-ALL, Notch-1 and FBXW7 Mutations Do Not Seem to Predict a Better Outcome in Adult Patients: Data from the UKALLXII/ECOG2993 Protocol

Marc R Mansour, MBChB, MRCP1*, Maria Luisa Sulis2*, Veronique Duke, PhD3*, Letizia Foroni3*, Sarah Jenkinson1*, Christopher G Allen1*, Rosemary E Gale1*, Georgina Buck4*, Sue Richards4*, Elisabeth Paietta5, Martin Tallman6*, Anthony H Goldstone, FRCP, FRCPath1*, Jacob M. Rowe, MD7, Adolfo A. Ferrando, MD, PhD2 and David C Linch1*

1Haematology, University College London, London, United Kingdom
2Institute for Cancer Genetics, Columbia University, New York, NY
3Department of Haematology, Imperial College, London, United Kingdom
4Ctsu, University of Oxford, Oxford, United Kingdom
5Cancer Center, Montefiore Medical Center North Division, Bronx, NY
6Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
7Hematology and Bone Marrow Transplantation, Rambam Health Care Campus and Technion, Israel Institute of Technology, Haifa, Israel., Haifa, Israel

Distinct Proteomic Signaling Networks Stratify Responses to Ara-C Based Induction Therapy in Patients with Acute Myeloid Leukemia (AML)

Mark Minden1, David Rosen2*, Santosh Putta2*, Aileen Cohen2*, Helen Francis-Lang2*, Todd Covey2*, John Woronicz2*, David Soper2*, Brian Long2*, James Cordeiro2*, Lootsie Panganiban-Lustan2*, Steve Banville2*, Urte Gayko2*, Alessandra Cesano2* and Wendy Fantl2*

1Princess Margaret Hospital, Toronto, ON, Canada
2Nodality Inc., S. San Francisco, CA

A Pilot Study for Using 3’-Deoxy-3’-[18f]Fluorothymidine Positron Emission Tomography ([18F]FLT  PET/CT) Imaging for Early Assessment of Response to Induction Chemotherapy in Acute Myeloid Leukemia (AML)

Mark B. Juckett, MD1, Matt Vanderhoek2*, Scott Perlman2*, Robert Nickles2* and Robert Jeraj2*

1Medicine, University of Wisconsin Hospitals and Clinic, Madison, WI
2Medicine, Univ. of WI Hospitals & Clinic, Madison, WI

Single IGH/TCR MRD Marker Is More Informative and Cost-Effective in Risk-Stratified Therapy for Childhood ALL: Prospective Treatment Trial Results from the Malaysia-Singapore (Ma-Spore) ALL 2003 Study

Allen Eng Juh Yeoh, MD1*, Hany Ariffin, MD2*, Ah Moy Tan, MD3*, Thi Thu Ha Truong, BSc1*, Hai Peng Lin, MD4*, Yiong Huak Chan, PhD5*, Shirley Kow Yin Kham, BSc1* and Thuan Chong Quah, MD1*

1Pediatrics, Yong Loo Lin School of Medicine, National University Health System, Singapore, Singapore
2Pediatrics, University of Malaya, Kuala Lumpur, Malaysia
3KK Women's and Children's Hospital, Singapore, Singapore
4Haematology, Subang Jaya Medical Center, Selangor Darul Ehsan, Malaysia
5Biostatistic Unit, Yong Loo Lin School of Medicine, National University Health System, Singapore, Singapore

Expression of Vascular Endothelial Growth Factor Receptors VEGFR-1 and VEGFR-2 Are Prognostic Factors in Normal Karyotype Acute Myeloid Leukemia (NK-AML)

Kellie M. Demock1*, Joseph Marinaro1*, Amanda Sobczyk1*, Laurie Ann Ford1*, Meir Wetzler, MD1, George Deeb, MD2, Lili Tian3* and Eunice S. Wang, MD1

1Medicine, Roswell Park Cancer Institute, Buffalo, NY
2Pathology and Lab Medicine, Roswell Park Cancer Institute, Buffalo, NY
3Biostatistics, Roswell Park Cancer Institute, Buffalo, NY

Hypoxia-Inducible Factor-1 Alpha (HIF-1α) and HIF-2α Are Independent Prognostic Factors for Normal Karyotype Acute Myeloid Leukemia (NK AML)

Kellie M. Demock1*, Joseph Marinaro1*, Ian McInnis1*, Laurie Ann Ford1*, Meir Wetzler, MD1, Lili Tian2*, George Deeb, MD3 and Eunice S. Wang, MD1

1Medicine, Roswell Park Cancer Institute, Buffalo, NY
2Biostatistics, Roswell Park Cancer Institute, Buffalo, NY
3Pathology and Lab Medicine, Roswell Park Cancer Institute, Buffalo, NY

*signifies non-member of ASH